MYCN oncogene is associated with aggressive disease course and poor outcome of NB patients [1,2,3,4,5], and c-MYC is activated as a potent oncogene in a well-defined subset of high-risk NB cases too [55]. The gene discussed is MYCN; the disease is neuroblastoma.